Navigation Links
Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Date:1/14/2008

America and Europe.

The company's second Phase 3 trial, VITAL-2, is a multi-center, randomized, controlled Phase 3 clinical trial designed to evaluate the safety and efficacy of GVAX immunotherapy for prostate cancer used in combination with Taxotere chemotherapy compared to the use of Taxotere chemotherapy and prednisone in HRPC patients with metastatic disease who are symptomatic with cancer-related pain. The primary endpoint of the trial is also an improvement in survival. VITAL-2 was initiated in June 2005 and is currently enrolling patients at approximately 90 sites in North America and Europe. The company expects to complete enrollment of approximately 600 patients in the first half of 2009 and if this is achieved, to have a sufficient number of events for a pre-planned interim analysis at that time.

The U.S. Food and Drug Administration (FDA) granted Cell Genesys Special Protocol Assessments (SPAs) for both VITAL-1 and VITAL-2. The SPA is a process that allows for official FDA evaluation of a Phase 3 clinical trial and provides trial sponsors with a binding written agreement that the design and analysis of the study are adequate to support a license application submission if that study is performed according to the SPA. Cell Genesys completed the modifications requested by FDA during the review process.

About GVAX Cancer Immunotherapies

GVAX cancer immunotherapies are non patient-specific investigational therapeutics comprised of whole tumor cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony stimulating factor), an immune stimulatory hormone, and then irradiated for safety. GVAX is designed to be administered through intradermal injections on an outpatient basis. To date, over 600 patients have been treated with GVAX cancer immunotherapies in Phase 1 and Phase 2 clinical trials for multiple indications, including prostate cancer, pancreatic cancer, and leukemia. The company is currently manufacturing GV
'/>"/>

SOURCE Cell Genesys, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
11. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... PARK, N.J. , July 30, 2015  Unichem ... voluntarily recalling one lot of Hydrochlorothiazide tablets 25 mg ... been initiated as a precautionary measure due to the ... of the product. The risk associated ... Hydrochlorothiazide tablet is the increased probability of experiencing Clopidogrel,s ...
(Date:7/30/2015)... July 30, 2015 PTC Therapeutics, Inc. (NASDAQ: ... reported financial results for the second quarter ending June ... many fronts across the organization.  We are excited to ... dystrophy clinical trial ever conducted with topline results expected ... Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is now ...
(Date:7/30/2015)... , July 30, 2015  Cleveland Clinic President ... 2015 keynote address last month that industry is compelled ... order to gain the efficiencies—and develop the transformational innovations ... Dr. Barsoum,s comments were preceded by Doug Kohrs ... and OMTEC moderator, who stressed that industry must add ...
Breaking Medicine Technology:Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2
... MUNDELEIN, Ill. , July 1 ... and information systems developer, today announces executive changes in ...  John Kershaw, President & CEO, Sysmex America Inc. has ... Secretary; Judy Bosko as Vice President of ...
... SCHAUMBURG, Ill. , July 1 ... today announced that the U.S. Food and Drug Administration ... sodium injection, USP. Heparin is a vital anticoagulant, preventing ... within the blood, routinely used in surgical and dialysis ...
Cached Medicine Technology:Sysmex America Announces Executive Leadership Changes 2FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP 2FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP 3FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP 4
(Date:8/1/2015)... , ... August 02, 2015 , ... Back packs can ... a school, however, back packs can wreck havoc on a kid's spine. With school ... supplies to and from school. Make sure you are aware of how to help ...
(Date:8/1/2015)... ... ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural Foods, was named one ... Federation, the largest retail trade association in the world, for her “advocacy and engagement” ... named as such. According to the NRF’s website, Retail Champions are “Main Street business ...
(Date:8/1/2015)... ... August 01, 2015 , ... BeverlyD, owner and founder of ... making hers the very first small business donation to kick off the campaign for ... thirty years. Her legacy includes a complete line of raw, organic hair care products, ...
(Date:7/31/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... strut their stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) ... trademark application in process. , To commemorate introduction of this new type of sod, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently touted ... in predictive health analytics , Jvion continues to disrupt the predictive analytic ... software that targets patient and population level illness to drive prevention and better ...
Breaking Medicine News(10 mins):Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Local Retail Advocate Wins National Recognition 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2
... Australia has earmarked $74 million to combat the bird flu ... Howard was to announce the funding in Busan, Korea, where ... forum., ,International agencies, like the World Health Organization (WHO), ... percent would go on a simulation exercise run by APEC ...
... had problems with the placenta during pregnancy are at an ... reports BBC online., ,Placenta is a tube through which ... mother and gets rid of waste products. , ,Doctor ... studied over a million women who were free from cardiovascular ...
... the World Health Organization (WHO) experts, concerted efforts, ... eradication of the five neglected tropical diseases from ... years. , WHO has identified five tropical ... (kala azar), soil transmitted helminths (STH) and yaws ...
... scientists present the first proof that simple exposure to cold weather ... your mother always warned you to wrap up warm to // ... point. , Scientists say they have the first proof that ... , Their study findings will appear in this week’s The ...
... the national nursing shortage by producing more qualified nursing ... Robert W. Woodruff Foundation has awarded // $995,000 to ... support its new doctorate of nursing practice program, the ... ,Thanking the Atlanta-based Woodruff Foundation, a private organization, for ...
... graduate, Leena Bahl Palomo, D.D.S and M.S.D, tracked 60 ... for osteoporosis and who had also visited the Case ... Case's department of Periodontology; and James Liu, chair of ... of Cleveland collaborated with Ms Palomo in the study. ...
Cached Medicine News:Health News:Placenta Problems In Pregnancy Linked To Early Heart Disease 2Health News:Concerted Effort Imperative For Elimination Of Tropical Diseases: WHO 2Health News:Scientist Affirm Mom’s Advice - Keep Yourself Wrapped Up To Avoid Cold 2Health News:Woodruff Foundation Grant To Support Doctorate Of Nursing Practice Program 2Health News:Drugs Used In Osteoporosis Can Help Prevent Periodontal Bone Loss 2
... a centimeter ruler etched into the gel tray ... includes apparatus, connecting cables, three 7x10 cm gel ... three 14-well combs. The Chameleon can accomodate up ... of a maximum of 120 samples with a ...
... of a Separation-Control unit for system control ... gel staining. The optional PhastTransfer Kit quickly ... unit. Electrophoresis is performed on a thermostatic ... 0 to +70 C. Multi-step programming capability ...
... The SEA 2000 apparatus and ready-to-use gels ... for analysis of nucleic acids by submerged ... complete this system, offering full compatibility and ... Besides the SEA 2000 and a unique ...
... SEA 2000 apparatus and ready-to-use gels are ... analysis of nucleic acids by submerged gel ... this system, offering full compatibility and optimal ... the SEA 2000 and a unique staining ...
Medicine Products: